CUPR News & Events

Cuprina Holdings announced that it plans to implement a 1-for-8 share consolidation of its Class A ordinary shares and Class B ordinary shares, effective on or around May 27. Beginning with the opening of trading on or around May 27, the company's Class A shares will begin trading on a post-share consolidation basis on the Nasdaq Capital Market under the same symbol " CUPR ", but under a new CUSIP number of G2592E110. "This action is an important step toward maintaining our Nasdaq listing and enhancing the Company's long-term financial flexibility. This approval reflects our shareholders' support for strengthening Cuprina's capital markets position as we continue advancing our biomedical and collagen-based technology portfolio," said Cuprina Chief Executive Officer David Quek.

Cuprina Holdings announced several strategic business developments, including a significant regulatory classification in Saudi Arabia and the expansion of its Medical and Scientific Advisory Board. Cuprina's 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority for MEDIFLY, the Company's medical-grade maggot debridement therapy. The SFDA has classified MEDIFLY as a Medical Device-Drug combination product, with the primary mode of action regulated under the medical device framework. This classification, which allows the Company to finalize the scientific and technical requirements necessary for the commercial distribution of MEDIFLY across Saudi Arabia's healthcare network, is a critical milestone in Cuprina's expansion strategy for the Middle East and North Africa region. The Company is also pleased to announce the appointment of Enming Yong to its Medical and Scientific Advisory Board. Dr. Yong is a highly respected Consultant in the Department of Endocrinology at Tan Tock Seng Hospital and serves as an Adjunct Senior Lecturer at the Lee Kong Chian School of Medicine, both located in Singapore.

Reports 6 month revenue $18,040 vs $30,184 last year. "Although our revenue decreased and our net loss increased compared with the same period last year, the first six months of 2025 allowed us to achieve significant advances in both diversifying our product and technology portfolio and expanding our geographic footprint," said Cuprina Chief Executive Officer, David Quek Yong Qi.